Limit search to items available for checkout
Title Glutamate-related biomarkers in drug development for disorders of the nervous system : workshop summary / Diana E. Pankevich, Miriam Davis, and Bruce M. Altevogt, rapporteurs ; Forum on Neuroscience and Nervous System Disorders, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
Imprint Washington, D.C. : National Academies Press, ©2011.


 Internet  Electronic Book    AVAILABLE
Description 1 online resource (xii, 61 pages) : illustrations (some color)
Bibliog. Includes bibliographical references (pages 39-43).
Note Available only to authorized UTEP users.
Print version record.
Subject Biochemical markers -- Congresses.
Drug development -- Congresses.
Nervous system -- Diseases -- Congresses.
Neuropharmacology -- Congresses.
Biomarkers, Pharmacological -- Congresses.
Central Nervous System Diseases -- diagnosis -- Congresses.
Central Nervous System -- drug effects -- Congresses.
Drug Discovery -- Congresses.
Glutamic Acid -- adverse effects -- Congresses.
Neuropharmacology -- methods -- Congresses.
Genre Electronic books.
Conference papers and proceedings.
Contents Introduction -- Overview of the Glutamatergic System -- Glutamate Biomarkers -- Treatment Implications of Biomarkers -- Challenges and Opportunities -- Appendix A: References -- Appendix B: Registered Attendees -- Appendix C: Agenda.
Summary Glutamate is the most pervasive neurotransmitter in the central nervous system (CNS). Despite this fact, no validated biological markers, or biomarkers, currently exist for measuring glutamate pathology in CNS disorders or injuries. Glutamate dysfunction has been associated with an extensive range of nervous system diseases and disorders. Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. These conditions are widespread, affecting a large portion of the United States population, and remain difficult to treat. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers. The Institute of Medicine's Forum on Neuroscience and Nervous System Disorders held a workshop on June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers. This book investigates promising current and emerging technologies, and outlines strategies to procure resources and tools to advance drug development for associated nervous system disorders. Moreover, this report highlights presentations by expert panelists, and the open panel discussions that occurred during the workshop.
Other Author Pankevich, Diana E., 1975-
Altevogt, Bruce M.
Davis, Miriam (Medical writer)
Institute of Medicine (U.S.). Forum on Neuroscience and Nervous System Disorders.
Other Title Print version: Glutamate-related biomarkers in drug development for disorders of the nervous system. Washington, D.C. : National Academies Press, ©2011 9780309212212